Serum titer of neutralizing antibodies after COVID-19 vaccination in Japanese patients with inflammatory bowel disease

Omicron variant of SARS‐CoV‐2: Genomics, transmissibility, and responses to current COVID‐19 vaccines

(2022) Yusha Araf et al.   JOURNAL OF MEDICAL VIROLOGY

SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting

(2021) Corey A Siegel et al.   GUT

Coronavirus disease 2019, immune-mediated inflammatory diseases and immunosuppressive therapies – A Danish population-based cohort study

(2021) Mohamed Attauabi et al.   JOURNAL OF AUTOIMMUNITY

Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD

(2021) Nicholas A Kennedy et al.   GUT

Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab

(2021) Nicholas A Kennedy et al.   GUT

Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis

(2021) Anuraag Jena et al.   AUTOIMMUNITY REVIEWS

Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2

(2021) Julien Favresse et al.   Viruses-Basel

Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study

(2021) Karin Cerna et al.   INFLAMMATORY BOWEL DISEASES

Escaping Pandora’s Box — Another Novel Coronavirus

(2020) David M. Morens et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association of Public Health Interventions With the Epidemiology of the COVID-19 Outbreak in Wuhan, China

(2020) An Pan et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Cell entry mechanisms of SARS-CoV-2

(2020) Jian Shang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients

(2020) Lakshmanane Premkumar et al.   Science Immunology

Effect of IBD medications on COVID-19 outcomes: results from an international registry

(2020) Ryan C Ungaro et al.   GUT

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

(2020) Merryn Voysey et al.   LANCET

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

(2020) Lindsey R. Baden et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risk and outcomes of coronavirus disease (COVID-19) in patients with inflammatory bowel disease: a systematic review and meta-analysis

(2020) Anupam Kumar Singh et al.   United European Gastroenterology Journal

Analytical and clinical performances of five immunoassays for the detection of SARS-CoV-2 antibodies in comparison with neutralization activity

(2020) Andrea Padoan et al.   EBioMedicine

Exacerbation of liver dysfunction in non-alcoholic steatohepatitis patients during the coronavirus disease 2019 (COVID-19) pandemic

(2020) Akira Asai et al.   JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION

Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases

(2018) Julien Kirchgesner et al.   GASTROENTEROLOGY

Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies

(2017) Siew C Ng et al.   LANCET

Crohn's disease

(2017) Joana Torres et al.   LANCET

Ulcerative colitis

(2017) Ryan Ungaro et al.   LANCET

Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease

(2014) J.F. Rahier et al.   Journal of Crohns & Colitis

Increased Risk of Pneumonia Among Patients With Inflammatory Bowel Disease

(2013) Millie D Long et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: Effects of combined therapy with immunosuppressants

(2012) G. Andrisani et al.   Journal of Crohns & Colitis

Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: A prospective study*

(2011) Gionata Fiorino et al.   INFLAMMATORY BOWEL DISEASES

Immunosuppression Impairs Response to Pneumococcal Polysaccharide Vaccination in Patients With Inflammatory Bowel Disease

(2009) Gil Y Melmed et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY